Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period

NCT02735044 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02735044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
April 14, 2016
Completion date
December 20, 2018
Enrollment
463 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus